The Technical Analyst
Vaxart Inc [VXRT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Vaxart Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
7.79% $0.710
America/New_York / 26 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 125.50 mill |
| EPS: | -0.570 |
| P/E: | -1.250 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 176.84 mill |
| Avg Daily Volume: | 1.953 mill |
| RATING 2024-04-26 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.250 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.21x |
| Company: PE -1.250 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.244 (-134.45%) $-0.954 |
| Date: 2024-04-26 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.607 - 0.813 ( +/- 14.52%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-03-28 | Tucker Sean | Buy | 0 | |
| 2024-03-28 | Tucker Sean | Sell | 3 902 | Common Stock |
| 2024-03-28 | Cummings James F. | Sell | 3 292 | Common Stock |
| 2024-03-18 | Tucker Sean | Buy | 90 000 | Common Stock |
| 2024-03-18 | Tucker Sean | Buy | 410 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 94.60 |
| Last 95 transactions |
| Buy: 10 890 181 | Sell: 279 805 |
Forecast:
16:00 - $0.710
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.710
Forecast 2: 16:00 - $0.710
Forecast 3: 16:00 - $0.710
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.710 (7.79% ) |
| Volume | 1.282 mill |
| Avg. Vol. | 1.953 mill |
| % of Avg. Vol | 65.66 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VXRT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:33 | buy | $1.200 | N/A | Active |
|---|
VXRT
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
Latest Press Releases
2024-03-27 08:00:00 - Press Release
Vaxart To Present At World Vaccine Congress Washington 2024 On April 3
South san francisco, calif., march 27, 2024 (globe newswire) -- vaxart, inc. (nasdaq: vxrt) today announced that dr. sean tucker, founder and chief scientific officer, will present at the world vaccine congress washington 2024 in washington, d.c. on wednesday, april 3, 2024. the company has appeared repeatedly at the annual event in washington, d.c.
2024-03-20 08:00:00 - Press Release
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
South san francisco, calif., march 20, 2024 (globe newswire) -- vaxart, inc. (nasdaq: vxrt) (the “company” or “vaxart”) today announced that the compensation committee of the board of directors approved certain equity awards to the company's new president and chief executive officer, steven lo, effective march 18, 2024. the awards were made pursuant to the company's previously disclosed offer letter with mr. lo, and as a material inducement to his joining the company as president and chief executive officer and a member of the board of directors.
2024-03-14 16:01:00 - Press Release
Vaxart Provides Business Update And Reports Full Year 2023 Financial Results
Significant progress made in preparing for a phase 2b study evaluating vaxart's oral pill xbb covid-19 vaccine against an approved mrna vaccine comparator
2024-03-07 08:00:00 - Press Release
Vaxart To Host Full Year 2023 Business Update And Financial Results Conference Call On March 14
South san francisco, calif., march 07, 2024 (globe newswire) -- vaxart, inc. (nasdaq: vxrt) today announced it will provide a business update and report financial results for the full year ended december 31, 2023 after the market close on thursday, march 14, 2024.
2024-03-06 08:00:00 - Press Release
Vaxart, Inc. Appoints Steven Lo As President, Chief Executive Officer, And Director
Michael j. finney, ph.d. to continue as chairman of the board of directors south san francisco, calif.
Latest News
2024-03-27 08:00:00 - GlobeNewsWire
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024. The Company has appeared repeatedly at the annual event in Washington, D.C.
2024-03-07 08:00:00 - GlobeNewsWire
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024.
2024-02-26 13:00:40 - Zacks Investment Research
VAXART, INC. (VXRT) is a Great Momentum Stock: Should You Buy?
Does VAXART, INC. (VXRT) have what it takes to be a top stock pick for momentum investors?
2024-02-23 10:11:05 - Zacks Investment Research
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
2024-02-20 10:56:13 - Zacks Investment Research
VAXART, INC. (VXRT) Now Trades Above Golden Cross: Time to Buy?
VAXART, INC. (VXRT) reached a significant support level, and could be a good pick for investors from a technical perspective.
2023-11-02 19:37:06 - Seeking Alpha
Vaxart, Inc. (VXRT) Q3 2023 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Edward Berg - Senior Vice President and General Counsel Conference Call Participants Mayank Mamtani - B. Riley Securities Liang Cheng - Jefferies Operator Greetings, and welcome to the Vaxart Business Update and Third Quarter 2023 Financial Results Conference Call.
2023-10-11 08:00:00 - GlobeNewsWire
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F. Cummings, Chief Medical Officer, will present at the World Vaccine Congress Europe 2023 in Barcelona, Spain on Wednesday, October 18 and Thursday, October 19, 2023.
2023-09-12 12:48:04 - InvestorPlace
3 Biotech Blockbusters to Turn $5,000 Into $50,000
Investing in biotech stock can provide investors with immense rewards but also substantial risks. The key is finding the right balance.
2023-08-15 15:26:39 - Zacks Investment Research
Bears are Losing Control Over VAXART, INC. (VXRT), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for VAXART, INC. (VXRT), indicating that the stock has found support.
2023-08-03 19:40:20 - Seeking Alpha
Vaxart, Inc. (VXRT) Q2 2023 Earnings Call Transcript
Start Time: 16:30 January 1, 0000 5:01 PM ET Vaxart, Inc. (NASDAQ:VXRT ) Q2 2023 Earnings Conference Call August 03, 2023, 16:30 PM ET Company Participants Andrei Floroiu - President and CEO James Cummings - Chief Medical Officer Sean Tucker - SVP and Chief Scientific Officer Phil Lee - CFO Brant Biehn - SVP and Business Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Mayank Mamtani - B. Riley Securities Operator Greetings, and welcome to the Vaxart Business Update and Second Quarter 2023 Financial Results Conference Call.